WO2007042983A3 - Fluridone as an anti-inflammatory agent - Google Patents
Fluridone as an anti-inflammatory agent Download PDFInfo
- Publication number
- WO2007042983A3 WO2007042983A3 PCT/IB2006/053669 IB2006053669W WO2007042983A3 WO 2007042983 A3 WO2007042983 A3 WO 2007042983A3 IB 2006053669 W IB2006053669 W IB 2006053669W WO 2007042983 A3 WO2007042983 A3 WO 2007042983A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluridone
- disclosed
- inflammatory activity
- active compound
- inflammatory agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a novel use of fluridone - compound known per se and used as an aquatic erbicide - in the medical field, in particular as an active compound for preparing a medicament having anti-inflammatory activity. Pharmaceutical compositions comprising fluridone as an active compound and pharmaceutically acceptable carriers and/or diluents are also disclosed. Finally, there is disclosed the pro-inflammatory activity of abscisic acid (ABA), a plant hormone which is also found in mammal serum and against which fluridone acts an an inhibitor.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/089,203 US7786042B2 (en) | 2005-10-07 | 2006-10-06 | Fluridone as an anti-inflammatory agent |
EP06821174A EP1948174B1 (en) | 2005-10-07 | 2006-10-06 | Fluridone as an anti-inflammatory agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000708A ITTO20050708A1 (en) | 2005-10-07 | 2005-10-07 | FLURIDONE AS AN ANTI-INFLAMMATORY AGENT |
ITTO2005A000708 | 2005-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007042983A2 WO2007042983A2 (en) | 2007-04-19 |
WO2007042983A3 true WO2007042983A3 (en) | 2007-07-26 |
Family
ID=37882171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/053669 WO2007042983A2 (en) | 2005-10-07 | 2006-10-06 | Fluridone as an anti-inflammatory agent |
Country Status (4)
Country | Link |
---|---|
US (1) | US7786042B2 (en) |
EP (1) | EP1948174B1 (en) |
IT (1) | ITTO20050708A1 (en) |
WO (1) | WO2007042983A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8389024B2 (en) * | 2005-06-22 | 2013-03-05 | Gonzalo Romero M. | Abscisic acid against cancer |
RU2361587C1 (en) * | 2008-02-14 | 2009-07-20 | Михаил Владимирович Кутушов | Medical product for treatment of oncologic diseases |
EP2391360B1 (en) * | 2009-01-28 | 2017-09-06 | Virginia Tech Intellectual Properties, Inc. | Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy |
CN105878224A (en) | 2010-09-17 | 2016-08-24 | 美商华仑生物科学公司 | Compositions Of Abscisic Acid For Animal Health |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3958025A (en) * | 1972-10-06 | 1976-05-18 | Livingston Virginia W C | Abscisic acid tablets and process |
EP0240257A2 (en) * | 1986-03-27 | 1987-10-07 | University of Lancaster | Compounds and pharmaceutical preparations having calcium - regulatory activity |
WO1998048808A1 (en) * | 1997-04-28 | 1998-11-05 | Parapro Llc, Limited Liability Company Of Indiana | Herbicide anti-apicomplexa protozoan parasite agents |
US20040117125A1 (en) * | 1999-04-26 | 2004-06-17 | Hao Chen | Drug discovery method and apparatus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329429B1 (en) * | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
-
2005
- 2005-10-07 IT IT000708A patent/ITTO20050708A1/en unknown
-
2006
- 2006-10-06 US US12/089,203 patent/US7786042B2/en not_active Expired - Fee Related
- 2006-10-06 EP EP06821174A patent/EP1948174B1/en not_active Not-in-force
- 2006-10-06 WO PCT/IB2006/053669 patent/WO2007042983A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3958025A (en) * | 1972-10-06 | 1976-05-18 | Livingston Virginia W C | Abscisic acid tablets and process |
EP0240257A2 (en) * | 1986-03-27 | 1987-10-07 | University of Lancaster | Compounds and pharmaceutical preparations having calcium - regulatory activity |
WO1998048808A1 (en) * | 1997-04-28 | 1998-11-05 | Parapro Llc, Limited Liability Company Of Indiana | Herbicide anti-apicomplexa protozoan parasite agents |
US20040117125A1 (en) * | 1999-04-26 | 2004-06-17 | Hao Chen | Drug discovery method and apparatus |
Also Published As
Publication number | Publication date |
---|---|
US20080242705A1 (en) | 2008-10-02 |
ITTO20050708A1 (en) | 2007-04-08 |
US7786042B2 (en) | 2010-08-31 |
EP1948174A2 (en) | 2008-07-30 |
EP1948174B1 (en) | 2012-08-01 |
WO2007042983A2 (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009033718A3 (en) | Use of anti -inflammatory peptide 1 as a therapeutic agent | |
WO2009043477A3 (en) | Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent | |
WO2009033732A3 (en) | Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent | |
WO2009033799A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033756A3 (en) | Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent | |
WO2009040036A3 (en) | Use of a galanin peptide as a therapeutic agent | |
CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2009039966A3 (en) | Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection | |
WO2009033735A3 (en) | Use of melanin concentrating hormone and met-enkephalin as therapeutic agents | |
WO2005007681A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
WO2009043507A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033665A3 (en) | Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent | |
WO2009043454A3 (en) | Use of pacap-27 as a therapeutic agent | |
WO2009033737A3 (en) | Use of gluten exorphin c : as a therapeutic agent | |
WO2009033767A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009040021A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009040017A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009040032A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009043480A3 (en) | Use of leptin (22-56 ) as a therapeutic agent | |
WO2009033722A8 (en) | Use of a octreotide as a therapeutic agent | |
WO2007042983A3 (en) | Fluridone as an anti-inflammatory agent | |
WO2009033729A3 (en) | Therapeutic uses of gastrin- 1 and g- pen-grgdspca | |
WO2009013901A1 (en) | Novel compound, method for production of the compound, pharmaceutical composition, anti-tumor agent, and use of the compound | |
WO2008093767A1 (en) | Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes | |
ATE355055T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING AN LTB4 INHIBITOR AND A COX-2 INHIBITOR OR A COX1/2 COMBINED INHIBITOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12089203 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006821174 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006821174 Country of ref document: EP |